H Lundbeck A/S traded at 31.81 this Wednesday June 15th, decreasing 1.19 or 3.61 percent since the previous trading session. Looking back, over the last four weeks, H Lundbeck A/S lost 0.73 percent. Over the last 12 months, its price rose by 0.73 percent. Looking ahead, we forecast H Lundbeck A/S to be priced at 30.59 by the end of this quarter and at 27.23 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alcon AG 67.84 -0.12 -0.18% 3.92%
Almirall SA 10.87 0.08 0.74% -28.01%
argenx SE 368.10 6.80 1.88% 39.43%
AstraZeneca 10,800.00 -8.00 -0.07% 23.84%
Bayer 55.52 -1.72 -3.00% 9.55%
Genmab 2,407.00 54.00 2.29% -8.41%
Galapagos 54.90 1.84 3.47% -5.08%
GN Store Nord 245.10 -5.60 -2.23% -57.00%
GRIFOLS 17.56 -0.28 -1.54% -21.61%
GlaxoSmithKline 1,786.60 -16.00 -0.89% 24.57%
Hikma Pharmaceutical 1,638.00 -16.00 -0.97% -35.94%
Lonza Group 529.60 4.80 0.91% -20.46%
Merck 167.85 2.45 1.48% 1.39%
Novartis 80.91 -0.74 -0.91% -4.31%
Orion 43.72 0.97 2.27% 17.97%
Recordati 42.91 -0.11 -0.26% -14.35%
Roche Holding 319.00 -3.60 -1.12% -9.76%
Sanofi 97.12 -1.22 -1.24% 11.93%
UCB 82.60 -0.04 -0.05% -6.92%
William Demant Holding 269.40 1.20 0.45% -26.47%

Indexes Price Day Year
Copenhagen 1657 -3.00 -0.18% -1.92%

H Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.